Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Cost Reimbursement
Drugs
Locations
Clinical Specialty
961-980 of 991 trials

Type 2 Diabetes: RO7795081 Medication Study

We are comparing a new medication, RO7795081, with a placebo and semaglutide in people with type 2 diabetes. The study aims to see how well it controls blood sugar and affects body weight.

Type 2 Diabetes6-12 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementDiabetologyEndocrinology

Immune Thrombocytopenia: NVG-2089 Treatment Study

We are testing a new intravenous treatment, NVG-2089, for individuals with Immune Thrombocytopenia. The study aims to evaluate its safety and how well it works in increasing platelet counts.

Immune Thrombocytopenia (ITP)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementHematology

Bone Health: Everolimus and Exercise for Postmenopausal Women

We are studying if a combination of a medication and resistance training can improve bone formation in healthy postmenopausal women. This research may help in understanding better ways to support bone health.

Healthy Elderly Women3-6 monthsEfficacy phase (II)6-10 visitsStandard MedicinesCost ReimbursementGynecology and ObstetricsOrthopedics and Traumatology

Head and Neck Cancer: NBTXR3 Treatment Study

We are studying a new treatment involving NBTXR3 with or without cetuximab for elderly patients with locally advanced head and neck cancer. The goal is to see if this approach improves survival compared to standard radiotherapy.

Head and Neck Cancer>2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Chronic Obstructive Pulmonary Disease: Verekitug Study

We are investigating whether Verekitug can help people with moderate-to-severe COPD manage their symptoms and improve lung function. The study will also assess the safety and overall impact on quality of life.

Chronic Obstructive Pulmonary Disease (COPD)>2 yearsEfficacy phase (II)>20 visitsInvestigational MedicinesCost ReimbursementPartially RemotePulmonology

Major Depressive Disorder: NBI-1065845 Treatment Study

We are evaluating a new medication to see if it helps maintain improvement in people with Major Depressive Disorder. This study looks at its effects on depressive symptoms and overall functioning.

Major Depressive DisorderConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemotePsychiatry

Hidradenitis Suppurativa: Sonelokimab Study

We are studying the long-term safety and effectiveness of sonelokimab for people with moderate to severe hidradenitis suppurativa. This research aims to improve symptoms and quality of life for participants.

Hidradenitis Suppurativa>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementDermatology

Advanced Breast Cancer: PF-07248144 with Fulvestrant

We are studying a new treatment combining PF-07248144 and fulvestrant for adults with hormone receptor-positive, HER2-negative advanced breast cancer. This trial aims to see if it helps patients whose cancer has progressed after prior therapy.

Hormone Receptor-Positive, HER2-Negative Breast CancerConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Alzheimer's Disease: KarXT + KarX-EC Treatment

We are studying a new combination treatment for agitation in people with Alzheimer's disease. The goal is to see if it can reduce agitation symptoms better than a placebo.

Alzheimer's Disease Agitation3-6 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPsychiatry

GSK5764227 for Advanced Gastrointestinal Tumors

We are studying a new treatment for patients with advanced unresectable or metastatic gastrointestinal tumors that have been previously treated. The trial aims to evaluate how well this treatment works and its safety.

Gastrointestinal Neoplasms6-12 monthsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboCost ReimbursementPartially RemoteGastroenterologyOncology

Nasopharyngeal Carcinoma: Imaging Study with [68Ga]Ga-DOTA-TOC

We are exploring a new imaging method to assess tumors in patients with EBV-related nasopharyngeal carcinoma. This study aims to improve treatment choices by understanding how the tumor responds to therapy.

Nasopharyngeal Carcinoma1-2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Ulcerative Colitis: RO7837195 Treatment Study

We are testing a new medication, RO7837195, for people with moderately to severely active ulcerative colitis. The study aims to see if it can help induce remission and how safe it is compared to a placebo.

Ulcerative Colitis>2 yearsEfficacy phase (II)Investigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Ulcerative Colitis: SAR441566 Study

We are investigating the effects of SAR441566 in adults with moderate-to-severe ulcerative colitis. The study aims to see if different doses can help achieve remission and improve overall health.

Ulcerative Colitis1-2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Inflammatory Rheumatic Diseases: JAK Inhibitor Dose Reduction Study

We are exploring if lowering the dose of JAK inhibitors is as effective as keeping the current dose for patients with rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis in low disease activity. This study will also look at safety and how many patients can successfully reduce their medication.

Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis1-2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Idiopathic Hypersomnia: ALKS 2680 Study

We are evaluating a new medication, ALKS 2680, for individuals with Idiopathic Hypersomnia to see if it helps reduce excessive daytime sleepiness and is safe to use.

Idiopathic Hypersomnia3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Congenital Pseudarthrosis of the Tibia: NVD003 Treatment Study

We are evaluating how effective and safe NVD003 is for children undergoing surgery for congenital pseudarthrosis of the tibia. The study will also look at its impact on bone healing and quality of life.

Congenital Pseudarthrosis>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOrthopedics and TraumatologyPediatrics

Multiple Sclerosis: Subcutaneous vs. Intravenous Ublituximab

We are studying how a new subcutaneous injection of ublituximab compares to the intravenous version for people with relapsing multiple sclerosis. The goal is to evaluate its safety and effectiveness in managing the condition.

Relapsing Multiple SclerosisConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementNeurology

Non-Small Cell Lung Cancer: RMC-9805 and RMC-6236 Study

We are studying a new treatment combination for patients with RAS G12D-mutant non-small cell lung cancer. The trial will evaluate the safety and effectiveness of these drugs alongside other anticancer therapies.

Non-small Cell Lung Cancer3-6 monthsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology

Type 2 Diabetes: Vicadrostat and Empagliflozin Study

We are testing the combination of vicadrostat and empagliflozin in people with type 2 diabetes, high blood pressure, and heart disease. The goal is to see if this combination can improve heart health compared to a placebo.

Type 2 DiabetesHypertensionCardiovascular Disease>2 yearsConfirmation phase (III)Investigational MedicinesCost ReimbursementPartially RemoteCardiologyEndocrinologyInternal Medicine

Acromegaly: ALXN2420 Treatment Study

We are studying whether the new drug ALXN2420 can help lower hormone levels and improve symptoms in adults with acromegaly when used with standard treatments. This trial compares ALXN2420 to a placebo to assess its effectiveness.

Acromegaly1-2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinology